Federal Register / Vol. 74, No. 199 / Friday, October 16, 2009 / Notices 53279 

guidance to the Director, CDC, and Director, 

CCID, in the following areas: program goals 

and objectives; strategies; program 

organization and resources for infectious 

disease prevention and control; and program 

priorities. 

Matters To Be Discussed: Agenda items 

will include: 

1. Working Groups: Environmental 

Microbiology, research to guide public health 

practice (National Center for Preparedness, 

Detection, and Control of Infectious Diseases; 

National Center for Immunization and 

Respiratory Diseases (NCIRD); and National 

Center for Zoonotic, Vector-Borne, and 

Enteric Diseases (NCZVED) Morning 

Session); Strategic Plan (National Center for 

HIV/AIDS, Viral Hepatitis, STD, and TB 

Prevention); Review of Funding provided 

through the American Recovery and 

Reinvestment Act of 2009 (ARRA) for 

immunization programs funded under 

Section 317 of the Public Health Service Act 

(NCIRD Afternoon Session); Strategic 

Framework and Program Reviews and 

Strategies (NCZVED Afternoon Session). 

2. Full Board: 

H1N1 discussion; announcements and 

introductions; and follow-up on actions 

recommended by the board. 

Agenda items are subject to change as 

priorities dictate. 

Written comments are welcome and should 

be received by the contact person listed 

below prior to the opening of the meeting. 

Contact Person For More Information: 

Harriette Lynch, Office of the Director, CCID, 

CDC, Mailstop E–77, 1600 Clifton Road, NE., 

Atlanta, Georgia 30333, e-mail: 

hlynch@cdc.gov, Telephone (404) 498–2726. 

The Director, Management Analysis and 

Services office has been delegated the 

authority to sign Federal Register notices 

pertaining to announcements of meetings and 

other committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Dated: October 8, 2009. 

Andre Tyler, 

Acting Director, Management Analysis and 

Services Office, Centers for Disease Control 

and Prevention. 

[FR Doc. E9–24937 Filed 10–15–09; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Health Resources and Services 

Administration; CDC/HRSA Advisory 

Committee on HIV and STD Prevention 

and Treatment 

In accordance with section l0(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), CDC and HRSA 

announce the following meeting of the 

aforementioned committee: 

Times and Dates: 

8 a.m.–5:30 p.m., November 2, 2009. 

8 a.m.–3 p.m., November 3, 2009. 

Place: Hyatt Regency Bethesda, 7400 

Wisconsin Avenue (One Bethesda Metro 

Center), Bethesda, Maryland 20814, 

Telephone: (301) 657–1234. 

Status: Open to the public, limited only by 

the space available. The meeting room will 

accommodate approximately 100 people. 

Purpose: This Committee is charged with 

advising the Director, CDC, and the 

Administrator, HRSA, regarding activities 

related to prevention and control of HIV/ 

AIDS and other STDs, the support of health 

care services to persons living with HIV/ 

AIDS, and education of health professionals 

and the public about HIV/AIDS and other 

STDs. 

Matters to be Discussed: Agenda items 

include issues pertaining to: (1) HIV/STD/ 

HCV Prevention, Treatment and Care in 

Federally Qualified Health Centers; (2) 

Biomedical Approaches to HIV Prevention— 

Pre-Exposure Prophylaxis; (3) Federal 

Adolescent Sexual Health Education 

Initiatives; and (4) Role of Surveillance in 

Informing CDC and HRSA Activities. 

Agenda items are subject to change as 

priorities dictate. 

Contact Person for More Information: 

Margie Scott-Cseh, Coordinating Center for 

Infectious Diseases, Strategic Business Unit, 

CDC, 1600 Clifton Road, NE., Mailstop E–07, 

Atlanta, Georgia 30333, Telephone: (404) 

639–8317. 

The Director, Management Analysis and 

Services Office, has been delegated the 

authority to sign Federal Register Notices 

pertaining to announcements of meetings and 

other committee management activities, for 

both the CDC and the Agency for Toxic 

Substances and Disease Registry. 

Dated: October 8, 2009. 

Andre Tyler, 

Acting Director, Management Analysis and 

Services Office, Centers for Disease Control 

and Prevention. 

[FR Doc. E9–24934 Filed 10–15–09; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2009–N–0664] 

Request for Nominations for Voting 

Members on Public Advisory Panels or 

Committees 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is requesting 

nominations for voting members to 

serve on the Device Good 

Manufacturing Practice Advisory 

Committee, certain device panels of the 

Medical Devices Advisory Committee, 

the National Mammography Quality 

Assurance Advisory Committee, and the 

Technical Electronic Products Radiation 

Safety Standards Committee in the 

Center for Devices and Radiological 

Health. Nominations will be accepted 

for current vacancies and those that will 

or may occur through August 31, 2010. 

FDA has a special interest in ensuring 

that women, minority groups, and 

individuals with disabilities are 

adequately represented on advisory 

committees and, therefore, encourages 

nominations of qualified candidates 

from these groups. 

DATES: Because scheduled vacancies 

occur on various dates throughout each 

year, no cutoff date is established for the 

receipt of nominations. However, when 

possible, nominations should be 

received at least 6 months before the 

date of scheduled vacancies for each 

year, as indicated in this notice. 

ADDRESSES: All nomination for 

membership should be sent 

electronically to CV@OC.FDA.GOV, or 

by mail to Advisory Committee 

Oversight & Management Staff (HF–4), 

5600 Fishers Lane, rm. 14C03, 

Rockville, MD 20857. Information about 

becoming a member on a FDA advisory 

committee can also be obtained by 

visiting FDA’s Web site at http:// 

www.fda.gov/AdvisoryCommittees/ 

default.htm. 

FOR FURTHER INFORMATION CONTACT: For 

specific Committee questions, contact 

the following persons listed in table 1 of 

this document. 


jlentini on DSKJ8SOYB1PROD with NOTICES
53280 Federal Register / Vol. 74, No. 199 / Friday, October 16, 2009 / Notices 

TABLE 1.—CONTACT INFORMATION FOR COMMITTEES AND PANELS

Contact Person Committee/Panel 

Geretta P. Wood, Center for Devices and Radiological Health, Food 

and Drug Administration, 10903 New Hampshire Ave., White Oak 

Bldg. 66, Room #1682, Silver Spring, MD 20993, 301–796–5550, email Geretta.Wood@fda.hhs.gov 

Device Panels of the Medical Devices Advisory Committee 

Normica Facey, Center for Devices and Radiological Health, Food and 

Drug Administration, 10903 New Hampshire Ave., White Oak Bldg. 

66, Room #4652, Silver Spring, MD 20993, e-mail: 

Normica.Facey@fda.hhs.gov 

National Mammography Quality Assurance Advisory Committee 

Collin L. Figueroa, Center for Devices and Radiological Health, Food 

and Drug Administration, 10903 New Hampshire Ave., White Oak 

Bldg. 66, Room #3438, Silver Spring, MD 20993, e-mail: 

Collin.Figueroa@fda.hhs.gov 

Device Good Manufacturing Practice Advisory Committee 

Richard V. Kaczmarek, Center for Devices and Radiological Health, 

Food and Drug Administration,10903 New Hampshire Ave., White 

Oak Bldg. 66, Room #4536, Silver Spring, MD 20993, e-mail: Richard.Kaczmarek@fda.hhs.gov 

Technical Electronic Product Radiation Safety Standards Committee 

SUPPLEMENTARY INFORMATION: I. Vacancies 

FDA is requesting nominations of 

voting members for vacancies listed as 

follows: 

TABLE 2.—COMMITTEE/PANEL EXPERTISE NEEDED AND VACANCIES

Committee/Panel expertise needed 

Current and 

Upcoming 

Vacancies 

Approximate Date 

Needed 

Anesthesiology and Respiratory Therapy Devices Panel of the Medical Devices Advisory Committee— 

anesthesiologists, pulmonary medicine specialists, or other experts who have specialized interests in 

ventilator support, pharmacology, physiology, or the effects and complications of anesthesia 

3 December 1, 2009 

Circulatory System Devices Panel of the Medical Devices Advisory Committee—interventional cardiologists, electrophysiologists, invasive (vascular) radiologists, vascular and cardiothoracic surgeons, 

and cardiologists with special interest in congestive heart failure 

1 July 1, 2010 

Clinical Chemistry and Clinical Toxicology Devices Panel of the Medical Devices Advisory Committee—doctors of medicine or philosophy with experience in clinical chemistry, clinical toxicology, 

clinical pathology, clinical laboratory medicine, endocrinology, and diabetes 

2 March 1, 2010 

Dental Products Panel of the Medical Devices Advisory Committee—dentists, engineers and scientists 

who have expertise in the areas of dental implants, dental materials, periodontology, tissue engineering, and dental anatomy 

3 

2 

Immediately 

November 1, 2009 

Medical Devices Dispute Resolution Panel of the Medical Devices Advisory Committee—experts with 

broad, cross-cutting scientific, clinical, analytical or mediation skills 

2 Immediately 

Ear, Nose and Throat Devices Panel of the Medical Devices Advisory Committee—otologists, 

neurotologists, audiologists 

1 Immediately 

Gastroenterology and Urology Devices Panel of the Medical Devices Advisory Committee—transplant 

specialists, gastroenterologists, urologists and nephrologists 

2 January 1, 2010 

General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee—surgeons 

(general, plastic, reconstructive, pediatric, thoracic, abdominal, pelvic and endoscopic); dermatologists; experts in biomaterials, lasers, wound healing, and quality of life; and biostatisticians 

2 

1 

Immediately 

September 1, 2010 

General Hospital and Personal Use Devices Panel of the Medical Devices Advisory Committee—internists, pediatricians, neonatologists, endocrinologists, gerontologists, nurses, biomedical engineers or 

microbiologists/infection control practitioners or experts 

3 January 1, 2010 

Hematology and Pathology Devices Panel of the Medical Devices Advisory Committee—hematologists 

(benign and/or malignant hematology), hematopathologists (general and special hematology, coagulation and homeostasis, and hematological oncology), gynecologists with special interests in gynecological oncology, cytopathologists, and molecular pathologists with special interests in development 

of predictive and prognostic biomarkers 

5 

1 

Immediately 

March 1, 2010 


jlentini on DSKJ8SOYB1PROD with NOTICES
Federal Register / Vol. 74, No. 199 / Friday, October 16, 2009 / Notices 53281 

TABLE 2.—COMMITTEE/PANEL EXPERTISE NEEDED AND VACANCIES—Continued 

Committee/Panel expertise needed 

Current and 

Upcoming 

Vacancies 

Approximate Date 

Needed 

Immunology Devices Panel of the Medical Devices Advisory Committee—persons with experience in 

medical, surgical, or clinical oncology, internal medicine, clinical immunology, allergy, molecular 

diagnostics, or clinical laboratory medicine 

3 Immediately 

Microbiology Devices Panel of the Medical Devices Advisory Committee—infectious disease clinicians, 

e.g., pulmonary disease specialists, sexually transmitted disease specialists, pediatric infectious disease specialists, experts in tropical medicine and emerging infectious diseases, biofilm development; mycologists; clinical microbiologists and virologists; clinical virology and microbiology laboratory directors, with expertise in clinical diagnosis and in vitro diagnostic assays, e.g., hepatologists; 

molecular biologists 

1 

3 

Immediately 

March 1, 2010 

Molecular and Clinical Genetics Devices Panel of the Medical Devices Advisory Committee—experts 

in human genetics and in the clinical management of patients with genetic disorders, e.g., pediatricians, obstetricians, neonatologists; individuals with training in inborn errors of metabolism, biochemical and/or molecular genetics, population genetics, epidemiology and related statistical training, and clinical molecular genetics testing (e.g., genotyping, array CGH, etc.); individuals with experience in genetics counseling, medical ethics; and individuals with experience in ancillary fields of 

study 

1 

1 

Immediately 

June 1, 2010 

Neurological Devices Panel of the Medical Devices Advisory Committee—neurosurgeons (cerebrovascular and pediatric), neurologists (stroke, pediatric, pain management, and movement disorders), 

interventional neuroradiologists, psychiatrists, and biostatisticians 

5 

2 

Immediately 

December 1, 2009 

Obstetrics and Gynecology Devices Panel of the Medical Devices Advisory Committee—experts in 

perinatology, embryology, reproductive endocrinology, pediatric gynecology, gynecological oncology, 

operative hysteroscopy, pelviscopy, electrosurgery, laser surgery, assisted reproductive technologies, contraception, postoperative adhesions, and cervical cancer and colposcopy; biostatisticians and engineers with experience in obstetrics/gynecology devices; urogynecologists; experts in 

breast care, gynecology in the older patient, diagnostic (optical) spectroscopy, midwifery, and labor 

and delivery nursing 

1 February 1, 2010 

Ophthalmic Devices Panel of the Medical Devices Advisory Committee—ophthalmologists specializing 

in cataract and refractive surgery and vitreo-retinal surgery, in addition to vision scientists, optometrists, and biostatisticians practiced in ophthalmic clinical trials 

3 November 1, 2009 

Orthopaedic and Rehabilitation Devices Panel of the Medical Devices Advisory Committee—orthopedic surgeons (joint, spine, trauma, and pediatric); rheumatologists; engineers (biomedical, biomaterials, and biomechanical); experts in rehabilitation medicine, sports medicine, and connective 

tissue engineering; and biostatisticians 

3 

2 

2 

Immediately 

Immediately 

September 1, 2010 

Radiological Devices Panel of the Medical Devices Advisory Committee—physicians with experience 

in general radiology, mammography, ultrasound, magnetic resonance, computed tomography, other 

radiological subspecialties and radiation oncology; scientists with experience in diagnostic devices, 

radiation physics, statistical analysis, digital imaging and image analysis 

2 February 1, 2010 

National Mammography Quality Assurance Advisory Committee—physicians, practitioners, or other 

health professionals whose clinical practice, research specialization, or professional expertise include a significant focus on mammography 

6 Immediately 

Device Good Manufacturing Practice Advisory Committee—vacancies include three government representatives, two public representatives and two health professionals 7 Immediately 

Technical Electronic Product Radiation Safety Standards Committee—vacancies include five government representatives, five industry representatives and five general public representatives 15 Immediately 

II. Functions 

A. Medical Devices Advisory Committee 

The committee reviews and evaluates 

data on the safety and effectiveness of 

marketed and investigational devices 

and makes recommendations for their 

regulation. The panels engage in a 

number of activities to fulfill the 

functions of the Federal Food, Drug, and 

Cosmetic Act (the act) envisions for 

device advisory panels. With the 

exception of the Medical Devices 

Dispute Resolution Panel, each panel, 

according to its specialty area performs 

the following duties: (1) Advises the 

Commissioner of Food and Drugs (the 

Commissioner) regarding recommended 

classification or reclassification of 

devices into one of three regulatory 

categories, (2) advises on any possible 

risks to health associated with the use 

of devices, (3) advises on formulation of 

product development protocols; (4) 

reviews premarket approval 

applications for medical devices, (5) 

reviews guidelines and guidance 

documents, (6) recommends exemption 

of certain devices from the application 

of portions of the act, (7) advises on the 

necessity to ban a device, and (8) 

responds to requests from the agency to 

review and make recommendations on 

specific issues or problems concerning 

the safety and effectiveness of devices. 

With the exception of the Medical 


jlentini on DSKJ8SOYB1PROD with NOTICES
53282 Federal Register / Vol. 74, No. 199 / Friday, October 16, 2009 / Notices 

Devices Dispute Resolution Panel, each 

panel, according to its specialty area, 

may also make appropriate 

recommendations to the Commissioner 

on issues relating to the design of 

clinical studies regarding the safety and 

effectiveness of marketed and 

investigational devices. 

The Dental Products Panel also 

functions at times as a dental drug 

panel. The functions of the dental drug 

panel are to evaluate and recommend 

whether various prescription drug 

products should be changed to over-thecounter status and to evaluate data and 

make recommendations concerning the 

approval of new dental drug products 

for human use. 

The Medical Devices Dispute 

Resolution Panel provides advice to the 

Commissioner on complex or contested 

scientific issues between FDA and 

medical device sponsors, applicants, or 

manufacturers relating to specific 

products, marketing applications, 

regulatory decisions and actions by 

FDA, and agency guidance and policies. 

The panel makes recommendations on 

issues that are lacking resolution, are 

highly complex in nature, or result from 

challenges to regular advisory panel 

proceedings or agency decisions or 

actions. 

B. National Mammography Quality 

Assurance Advisory Committee 

The functions of the committee are to 

advise FDA on the following topics: (1) 

Developing appropriate quality 

standards and regulations for 

mammography facilities; (2) developing 

appropriate standards and regulations 

for bodies accrediting mammography 

facilities under this program; (3) 

developing regulations with respect to 

sanctions; (4) developing procedures for 

monitoring compliance with standards; 

(5) establishing a mechanism to 

investigate consumer complaints; (6) 

reporting new developments concerning 

breast imaging which should be 

considered in the oversight of 

mammography facilities; (7) 

determining whether there exists a 

shortage of mammography facilities in 

rural and health professional shortage 

areas and determining the effects of 

personnel on access to the services of 

such facilities in such areas; (8) 

determining whether there will exist a 

sufficient number of medical physicists 

after October 1, 1999, and (9) 

determining the costs and benefits of 

compliance with these requirements. 

C. Device Good Manufacturing Practice 

Advisory Committee 

The functions of the committee are to 

review proposed regulations issuance 

regarding good manufacturing practices 

governing the methods used in, and the 

facilities and controls used for 

manufacture, packaging, storage, 

installation, and servicing of devices, 

and make recommendations regarding 

the feasibility and reasonableness of 

those proposed regulations. The 

committee also reviews and makes 

recommendations on proposed 

guidelines developed to assist the 

medical device industry in meeting the 

good manufacturing practice 

requirements, and provides advice with 

regard to any petition submitted by a 

manufacturer for an exemption or 

variance from good manufacturing 

practice regulations. 

Section 520 of the act, (21 U.S.C. 

360(j)), as amended, provides that the 

Device Good Manufacturing Practice 

Advisory Committee shall be composed 

of nine members as follows: (1) Three of 

the members shall be appointed from 

persons who are officers or employees 

of any Federal, State, or local 

government; (2) two shall be 

representatives of the interests of the 

device manufacturing industry: (3) two 

shall be representatives of the interests 

of physicians and other health 

professionals; and (4) two shall be 

representatives of the interests of the 

general public. The agency will publish 

a separate notice announcing the 

vacancies of two representatives of 

interests of the device manufacturing 

industry as they become available. 

D. Technical Electronic Product 

Radiation Safety Standards Committee 

The function of the committee is to 

provide advice and consultation on the 

technical feasibility, reasonableness, 

and practicability of performance 

standards for electronic products to 

control the emission of radiation from 

such products. The committee may 

recommend electronic product radiation 

safety standards for consideration. 

Section 534(f) of the act (21 U.S.C. 

360kk(f)), as amended by the Safe 

Medical Devices Act of 1990, provides 

that the Technical Electronic Product 

Radiation Safety Standards Committee 

include five members from 

governmental agencies, including State 

or Federal Governments, five members 

from the affected industries, and five 

members from the general public, of 

which at least one shall be a 

representative of organized labor. 

III. Qualifications 

A. Panels of the Medical Devices 

Advisory Committee 

Persons nominated for membership 

on the panels should have adequately 

diversified experience appropriate to 

the work of the panel in such fields as 

clinical and administrative medicine, 

engineering, biological and physical 

sciences, statistics, and other related 

professions. The nature of specialized 

training and experience necessary to 

qualify the nominee as an expert 

suitable for appointment may include 

experience in medical practice, 

teaching, and/or research relevant to the 

field of activity of the panel. The 

particular needs at this time for each 

panel are listed in section I of this 

document. The term of office is up to 4 

years, depending on the appointment 

date. 

B. National Mammography Quality 

Assurance Advisory Committee 

Persons nominated for membership 

should be physicians, practitioners, and 

other health professionals, whose 

clinical practice, research 

specialization, or professional expertise 

include a significant focus on 

mammography and individuals 

identified with consumer interests. Prior 

experience on Federal public advisory 

committees in the same or similar 

subject areas will also be considered 

relevant professional expertise. The 

particular needs at this time for this 

committee are listed in section I of this 

document. The term of office is up to 4 

years, depending on the appointment 

date. 

C. Device Good Manufacturing Practice 

Advisory Committee 

Persons nominated for membership as 

a health professional or officer or 

employee of any Federal, State, or local 

government should have knowledge of 

or expertise in any one or more of the 

following areas: Quality assurance 

concerning the design, manufacture, 

and use of medical devices. To be 

eligible for selection as a representative 

of the general public, nominees should 

possess appropriate qualifications to 

understand and contribute to the 

committee’s work. The particular needs 

at this time for this committee are listed 

in section I of this document. The term 

of office is up to 4 years, depending on 

the appointment date. 

D. Technical Electronic Product 

Radiation Safety Standards Committee 

Persons nominated should be 

technically qualified by training and 

experience in one or more fields of 

science or engineering applicable to 

electronic product radiation safety. The 

particular needs at this time for this 

committee are listed in section I of this 

document. The term of office is up to 4 


jlentini on DSKJ8SOYB1PROD with NOTICES
Federal Register / Vol. 74, No. 199 / Friday, October 16, 2009 / Notices 53283 

years, depending on the appointment 

date. 

IV. Nomination Procedures 

Any interested person may nominate 

one or more qualified persons for 

membership on one or more of the 

advisory panels or advisory committees. 

Self-nominations are also accepted. 

Nominations must include a current, 

complete resume or curriculum vitae of 

each nominee, current business and/or 

home address, telephone number, and email address if available. Nominations 

must specify the advisory panel(s) or 

advisory committee(s) for which the 

nominee is recommended. Nominations 

must also acknowledge that the 

nominee is aware of the nomination, 

unless self-nominated. FDA will ask 

potential candidates to provide detailed 

information concerning such matters as 

financial holdings, employment, and 

research grants and/or contracts. 

This notice is issued under the 

Federal Advisory Committee Act (5 

U.S.C. app. 2) and 21 CFR part 14 

relating to advisory committees. 

Dated: October 9, 2009. 

David Horowitz, 

Assistant Commissioner for Policy. 

[FR Doc. E9–24896 Filed 10–15–09; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Environmental 

Health Sciences; Request for 

Nominations for Voting Members To 

Serve on the National Institutes of 

Health (NIH), National Institute of 

Environmental Health Sciences’ 

(NIEHS) Interagency Breast Cancer 

and Environmental Research 

Coordinating Committee 

SUMMARY: The National Institute of 

Environmental Health Sciences of the 

National Institutes of Health is 

requesting nominations for members to 

serve on the Interagency Breast Cancer 

and Environmental Research 

Coordinating Committee. This 

Committee will coordinate information 

on existing activities related to breast 

cancer and environmental research and 

make recommendations to the National 

Institutes of Health and other Federal 

agencies on how to improve existing 

research programs. 

DATES: Nominations received on or 

before December 1, 2009 will be 

considered in a pool of candidates 

gathered from numerous sources for 

membership on the Committee. 

Nominations received after December 1, 

2009 will be considered for future 

vacancies. 

ADDRESSES: All nominations for 

membership should be sent to the 

contact person listed in the FOR FURTHER

INFORMATION CONTACT section of this 

document. 

FOR FURTHER INFORMATION CONTACT: 

Jennifer Collins, Division of Extramural 

Research and Training, National 

Institute of Environmental Health 

Sciences, P.O. Box 12233, MD K3–12, 

RTP, NC 27709, Phone: 919–541–0117, 

FAX: 919–316–4606, E-mail: 

collins6@niehs.nih.gov. 

I. Function of the Interagency Breast 

Cancer and Environmental Research 

Coordinating Committee 

The Committee will (1) share and 

coordinate information on existing 

research activities, and make 

recommendations to the National 

Institutes of Health and other Federal 

agencies regarding how to improve 

existing research programs, that are 

related to breast cancer research; (2) 

develop a comprehensive strategy and 

advise the NIH and other Federal 

agencies in the solicitation of proposals 

for collaborative, multidisciplinary 

research, including proposals to 

evaluate environmental and genomic 

factors that may be related to the 

etiology of breast cancer; (3) develop a 

summary of advances in breast cancer 

research supported or conducted by 

Federal agencies relevant to the 

diagnosis, prevention, and treatment of 

cancer and other diseases and disorders; 

and (4) make recommendations to the 

Secretary regarding any appropriate 

changes to research activities, to ensure 

that federal research activities are free of 

unnecessary duplication of effort, 

regarding public participation in 

decisions relating to breast cancer 

research to increase the involvement of 

patient advocacy and community 

organizations representing a broad 

geographical area, on how best to 

disseminate information on breast 

cancer research progress, and how to 

expand partnerships between public 

and private entities to expand 

collaborative, cross-cutting research. 

II. Criteria for Voting Members 

A. Scientists, Physicians, and Other 

Health Professionals 

Committee Members will include 

scientists, physicians, and health 

professionals who are not officers or 

employees of the United States; 

represent multiple disciplines, 

including clinical, basic, and public 

health sciences; represent different 

geographical regions of the United 

States; are from practice settings, 

academia, or other research settings; and 

are experienced in the scientific peer 

review process. 

B. Other Public Members 

Committee Members will also include 

members of the general public, who 

represent individuals with breast 

cancer. 

III. Nomination Procedures 

Any interested person may nominate 

one or more qualified persons for 

membership on the Interagency Breast 

Cancer and Environmental Research 

Coordinating Committee. Selfnominations are also accepted. In an 

effort to ensure that women, minority 

groups, and individuals with disabilities 

are adequately represented on advisory 

committees, NIEHS encourages 

nominations of qualified candidates 

from these groups. Nominations must 

include a current resume or curriculum 

vitae of each nominee, including current 

business address, telephone number, 

and email address, and a brief 

explanation of the nominee’s 

qualifications for the committee. 

Experience and activity on boards, 

committees, and/or membership in 

advocacy groups dealing with breast 

cancer and the environment, 

participation in the review process for 

federal programs, and/or involvement 

with programs regarding the support of 

scientific research in this area should be 

indicated. Nominations must also 

acknowledge that the nominee is aware 

of the nomination, is willing to serve as 

a member, and appears to have no 

conflict of interest that would preclude 

membership. NIEHS will ask the 

potential candidates to provide detailed 

information concerning matters related 

to financial holdings, employment, and 

research grants and/or contracts. 

Dated: October 8, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–24969 Filed 10–15–09; 8:45 am] 

BILLING CODE 4140–01–P 


jlentini on DSKJ8SOYB1PROD with NOTICES